Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Evaluation of the Safety and Efficacy of TLD in Patients with COPD
NCT03639051 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System (Nuvaira System) in the treatment of COPD.
Conditions Studied
Interventions
- DEVICE Targeted Lung Denervation (TLD)
- OTHER Optimal Medical Care
Study Locations (20)
California
- UC Davis — Sacramento
- Harbor UCLA — Torrance
Illinois
- University of Chicago — Chicago
- Suburban Lung Associates — Elk Grove Village
Michigan
- University of Michigan — Ann Arbor
- Spectrum Health Medical Group — Grand Rapids
North Carolina
- Duke University — Durham
- First Health of the Carolinas — Pinehurst
Pennsylvania
- Temple Lung Center — Philadelphia
- University of Pittsburgh Medical Center (UPMC) — Pittsburgh
Texas
- St. Davids HealthCare — Georgetown
- Houston Methodist Hospital — Houston
Alabama
- University of Alabama at Birmingham (UAB) Lung Health Center — Birmingham
Arizona
- HonorHealth — Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2019-05-23 |
| Est. Completion | 2028-09 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03639051
The ClinicalTrials.gov registry entry for NCT03639051 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 464 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nuvaira, which has 33 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with COPD appearing as the primary indexed condition, and to 2 interventions — of which Targeted Lung Denervation (TLD) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03639051 reports 20 study locations spanning 14 distinct geographic areas — top geographies include California, Illinois, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03639051 about?
NCT03639051 is a clinical study titled "Evaluation of the Safety and Efficacy of TLD in Patients with COPD". The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System (Nuvaira System) in the treatment of COPD.
What is the current status of trial NCT03639051?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 464 participants. The study started on 2019-05-23. Estimated completion is 2028-09.
What conditions does trial NCT03639051 study?
This clinical trial studies the following conditions: COPD. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03639051?
The interventions under investigation include: Targeted Lung Denervation (TLD) (DEVICE), Optimal Medical Care (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03639051?
This trial is sponsored by Nuvaira, which has 33 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03639051 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.